Craft

BenevolentAI

Market Valuation

$1 B

2017-05-02

Total Funding

$305 M

Revenue

€7.3 M

FY, 2023

BenevolentAI Summary

Company Summary

Overview
BenevolentAI is a clinical-stage AI-enabled drug discovery company. It offers a Benevolent Platform that features clinical sub-typing, biomarker assessment, experimental hypothesis validation, indication expansion and drug repurposing, etc.
Type
Private
Status
Active
Founded
2013
HQ
London, GB | view all locations
Website
https://www.benevolent.com/
Cybersecurity rating
Sectors

Key People

  • Olivier Brandicourt

    Olivier Brandicourt, Non-Executive Director

    • Susan Liautaud

      Susan Liautaud, Non-Executive Director

      • Ivan Griffin

        Ivan Griffin, COO and Co-Founder

      • Nigel Shadbolt

        Nigel Shadbolt, Non-Executive Director

        Operating MetricsView all

        Trademarks Pending

        2

        May, 2020

        LocationsView all

        2 locations detected

        • London, England HQ

          United Kingdom

          4-8 Maple St, Bloomsbury

        • Babraham, England

          United Kingdom

          Babraham Hall House

        BenevolentAI Financials

        Summary Financials

        Revenue (H1, 2024)
        €2.8M
        Gross profit (H1, 2024)
        €935.0K
        Net income (H1, 2024)
        (€24.8M)
        Cash (H1, 2024)
        €23.0M
        EBIT (H1, 2024)
        (€32.3M)
        Enterprise value
        $977.0M

        Footer menu